DOCSLIB.ORG

In Vitro Activities of 11 Antimicrobial Agents Against Macrolide-Resistant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Vitro Activities of 11 Antimicrobial Agents Against Macrolide-Resistant Jpn. J. Infect. Dis., 65, 535-538, 2012 Short Communication In Vitro Activities of 11 Antimicrobial Agents against Macrolide-Resistant Mycoplasma pneumoniae Isolates from Pediatric Patients: Results from a Multicenter Surveillance Study Hiroto Akaike1, Naoyuki Miyashita2*,MikaKubo1, Yasuhiro Kawai1, Takaaki Tanaka1, Satoko Ogita1, Kozo Kawasaki1, Takashi Nakano1,KiheiTerada1, Kazunobu Ouchi1, and the Atypical Pathogen Study Group** 1Department of Pediatrics and 2Department of Internal Medicine 1, Kawasaki Medical School, Okayama 700-8505, Japan (Received April 12, 2012. Accepted July 11, 2012) SUMMARY: Macrolide-resistant Mycoplasma pneumoniae is emerging in several countries, and it is mainly observed in children. To our knowledge, we conducted the first multicenter prospective epidemiological study of macrolide-resistant M. pneumoniae in order to investigate regional differences in the susceptibility of macrolide-resistant M. pneumoniae to antibacterial agents. The in vitro activities of 11 antimicrobial agents against macrolide-resistant M. pneumoniae isolates from 5 different areas of Japan were investigated. Among 190 M. pneumoniae isolates from pediatric patients, 124 (65.2z)iso- lates showed macrolide resistance and possessed an A2063G transition in domain V of the 23S rRNA. These isolates showed high resistance to erythromycin, clarithromycin, and azithromycin with minimum inhibitory concentrations (MICs) Æ16 mg/ml. Conversely, quinolones such as garenoxacin, moxifloxa- cin, tosufloxacin, and levofloxacin exhibited potent antimycoplasmal activity. No regional differences were observed with respect to the MICs among the 5 areas in Japan. Mycoplasma pneumoniae is a major causative patho- pneumonia isolates had mutations in domain V of the gen of respiratory tract infections, and it is found 23S rRNA gene (1,2,10,11). Several studies indicated mainly in children and younger adults. Although the 14- that macrolide resistance in M. pneumoniae may have and 15-membered macrolides are generally considered clinical significance in terms of diminished response to as the first-choice agents against M. pneumoniae infec- treatment with drugs in this class (2,12,13). In Japan, tions in children, it has been reported that more than reports of macrolide-resistant M. pneumoniae were 40z of M. pneumoniae isolates are resistant to macro- from limited areas, and there have been no large-scale lides in Japan (1,2). Macrolide-resistant M. pneumoniae epidemiological studies conducted throughout Japan. is also emerging in several other countries, primarily in The purpose of the present study was to investigate children (3–9). During an outbreak of M. pneumoniae regional differences in the susceptibility of macrolide- infections in Italy in 2010, 11 (25.5z) of the 43 hospital- resistant M. pneumoniae to antibacterial agents. Thus, ized pediatric patients with M. pneumoniae were macro- to our knowledge, this is the first multicenter prospec- lide resistant (4). In particular, the reported incidence of tive epidemiological study of macrolide-resistant M. macrolide-resistant M. pneumoniae is more than 90z in pneumoniae. China (6). Thus, the increasing resistance of M. pneu- We enrolled all pediatric patients with acute respira- moniae to commonly used 14- and 15-membered macro- tory tract infections who visited 62 institutions located lides is a growing concern. in 5 areas of Japan (20 institutions in Kyushu, 25 in Specific point mutations in domain V of the 23S Chugoku, 3 in Shikoku, 11 in Kinki, and 3 in Hok- rRNA gene of M. pneumoniae define the macrolide- kaido), participating in the Atypical Pathogen Study resistant phenotypes. The mutations that induce a high Group from November 2009 to August 2011 (Fig. 1). level of macrolide resistance are an A to G transition at Pediatricians at the facilities collected samples from position 2063 and an A to C transition at position 2064; patients with suspected M. pneumoniae infections. In- whereas, low-level resistance is induced by a C to A or G formed consent was obtained from the parents of all transition at position 2617 and an A to T transition at patients. The Ethics Committee at Kawasaki Medical position 2063 (1,9). All of the macrolide-resistant M. School approved the study protocol. M. pneumoniae isolates were obtained by cultivation of specimens. The medium used for isolation and deter- *Corresponding author: Mailing address: Department of mination of the minimum inhibitory concentration Internal Medicine I, Kawasaki Medical School, 2-1-80 (MIC) was pleuropneumonia-like organism broth Nakasange, Kita-ku, Okayama 700-8505, Japan. Tel: (PPLO;Oxoid,Franklin,N.J.,USA)supplemented ＋81-86-225-2111, Fax: ＋81-86-232-8343, E-mail: nao＠ with 0.5z glucose (Wako Pure Chemicals Inc., Osaka, med.kawasaki-m.ac.jp Japan), 20z Mycoplasma supplement-G (Oxoid), and **Members of the Atypical Pathogen Study Group are 0.0025z phenol red (Sigma-Aldrich Co. LLC., St. listed in the Appendix. Louis, Mo., USA). 535 Table 1. Prevalence of Mycoplasma pneumoniae isolates in 5 areas of Japan Area No. of No. of No. of resistant samples tested isolates (z) isolates (z) Kyushu 160 37 (23.1) 28 (75.6) Chugoku 550 73 (13.2) 39 (53.4) Shikoku 57 19 (33.3) 19 (100) Kinki 104 20 (19.2) 5 (25.0) Hokkaido 161 41 (27.3) 33 (80.4) Total 1,032 190 (18.4) 124 (65.2) Table 2. Baseline characteristics of the patients with Mycoplas- ma pneumoniae infections Macrolide-resistant Macrolide-sensitive M. pneumoniae M. pneumoniae P No. 124 66 Age, mean ± SD (y) 8.5±4.3 7.1±4.4 0.098 Gender, male 74 (59) 41 (62) 0.758 Fig. 1. Samples were collected from pediatric patients with acute Disease classification respiratory tract infections who visited 62 institutions located Pneumonia 75 (60) 42 (63) 0.754 in 5 areas of Japan, i.e., Kyushu area, Chugoku area, Shikoku Bronchitis 49 (40) 24 (37) area, Kinki area, and Hokkaido area. Data represent the numbers of patients, and numbers in paren- theses are percentages. The MICs of the 11 antimicrobial agents for the iso- lates were determined by micro-dilution methods (14). Briefly, medium containing 105–106 CFU/ml of M. ences in terms of age, gender, or disease classification pneumoniae was placed in 96-well microplates and incu- between the macrolide-resistant and macrolide-sensitive bated at 379C for 6–8 days. The MIC was defined as the M. pneumoniae groups. Table 3 shows the MIC range, lowest concentration of antimicrobial agents at which MIC50,andMIC90 for the 11 agents according to the the metabolism of the organism was inhibited as evi- presence or absence of a mutation in the 23S rRNA gene denced by a lack of color change in the medium when in the 190 M. pneumoniae isolates. Among the 124 iso- the drug-free control first showed a color. Reference lates that were with macrolide resistant, the MIC50 and strain FH was used as drug-susceptible control. The an- MIC90 values for 14- and 15-membered macrolides timicrobial agents used for MIC determination were as (e.g., erythromycin, clarithromycin, and azithromycin) follows: erythromycin, clarithromycin, azithromycin, were 64 mg/ml to À128 mg/ml and 128 mg/ml to À128 rokitamycin, clindamycin, minocycline, tetracycline, mg/ml, respectively. Compared to the 14- and 15-mem- tosufloxacin, garenoxacin, levofloxacin, and moxiflox- bered macrolides, the 16-membered macrolide, acin. rokitamycin, had moderate-level resistance, with MIC50 Specific point mutations in domain V of the 23S and MIC90 values of 0.25 mg/ml and 0.5 mg/ml, respec- rRNA gene of M. pneumoniae define the macrolide- tively. Higher MIC values are reported for rokitamycin resistance phenotypes. We performed full-length se- in the other mutations such as A2064G and A2063C in quencing of the 23S rRNA gene in M. pneumoniae domain V of the 23S rRNA gene (1). Conversely, all isolates showing macrolide resistance, as reported quinolones, especially garenoxacin and moxifloxacin, previously (11). showed excellent antimycoplasmal activity, with MIC50 Statistical analysis was performed using Stat View values of 0.0313 mg/ml and 0.0625 mg/ml, respectively, version 5.0. (SAS Institute Inc., Cary, N.C., USA). The and MIC90 values of 0.0625 mg/ml and 0.125 mg/ml, re- number of patients per gender and disease classification spectively, against macrolide-resistant M. pneumoniae was compared using the Fisher's exact test. We used the isolates; these values were equal to that against macro- Wilcoxon rank-sum test to compare the mean age of lide-sensitive M. pneumoniae isolates. Tosufloxacin, the patients. P values less than 0.05 were statistically sig- only quinolone approved for treatment of pneumonia in nificant. pediatric patients in Japan, also showed good an- A total of 190 (18.4z)isolatesofM. pneumoniae timycoplasmal activity against the macrolide-resistant were obtained by cultivation of samples from 1,032 isolates. The MIC50 and MIC90 values were 0.25 mg/ml pediatric patients with respiratory tract infections (37 and 0.5 mg/ml, respectively. There were no regional samples were obtained in Kyushu, 73 in Chugoku, 19 in differences among the 5 areas in Japan with respect to Shikoku, 20 in Kinki, and 41 in Hokkaido) (Table 1). the MIC values. Of the 190 isolates, 124 (65.2z) were classified as mac- A2063G in domain V of the 23S rRNA is the most fre- rolide-resistant M. pneumoniae by genetic analysis, and quent mutation association with macrolide resistance, all had the point mutation A2063G in domain V of the followed by A2064G. The A2063C, C2617G, C2617A, 23S rRNA gene. Patient characteristics are shown in and A2063T mutations are rare (1,2,9). All macrolide- Table 2. There were no statistically significant differ- resistant isolates in the present study had the same mu- 536 Table 3. In vitro antimycoplasmal activity against clinical isolates of Mycoplasma pneumoniae according to the presence or absence of a mutation in the 23S rRNA gene MIC (mg/ml) for: Macrolide-sensitive M.
Load more

Recommended publications
  • Nature Nurtures the Design of New Semi-Synthetic Macrolide Antibiotics
    The Journal of Antibiotics (2017) 70, 527–533 OPEN Official journal of the Japan Antibiotics Research Association www.nature.com/ja REVIEW ARTICLE Nature nurtures the design of new semi-synthetic macrolide antibiotics Prabhavathi Fernandes, Evan Martens and David Pereira Erythromycin and its analogs are used to treat respiratory tract and other infections. The broad use of these antibiotics during the last 5 decades has led to resistance that can range from 20% to over 70% in certain parts of the world. Efforts to find macrolides that were active against macrolide-resistant strains led to the development of erythromycin analogs with alkyl-aryl side chains that mimicked the sugar side chain of 16-membered macrolides, such as tylosin. Further modifications were made to improve the potency of these molecules by removal of the cladinose sugar to obtain a smaller molecule, a modification that was learned from an older macrolide, pikromycin. A keto group was introduced after removal of the cladinose sugar to make the new ketolide subclass. Only one ketolide, telithromycin, received marketing authorization but because of severe adverse events, it is no longer widely used. Failure to identify the structure-relationship responsible for this clinical toxicity led to discontinuation of many ketolides that were in development. One that did complete clinical development, cethromycin, did not meet clinical efficacy criteria and therefore did not receive marketing approval. Work on developing new macrolides was re-initiated after showing that inhibition of nicotinic acetylcholine receptors by the imidazolyl-pyridine moiety on the side chain of telithromycin was likely responsible for the severe adverse events.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics Alexander A
    Alexander A. Vinks · Hartmut Derendorf Johan W. Mouton Editors Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics Alexander A. Vinks • Hartmut Derendorf Johan W. Mouton Editors Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics Editors Alexander A. Vinks Hartmut Derendorf Division of Clinical Pharmacology Department of Pharmaceutics Cincinnati Children’s Hospital University of Florida Medical Center and Department of Gainesville College of Pharmacy Pediatrics Gainesville , FL , USA University of Cincinnati College of Medicine Cincinnati , OH , USA Johan W. Mouton Department of Medical Microbiology Radboudumc, Radboud University Nijmegen Nijmegen, The Netherlands ISBN 978-0-387-75612-7 ISBN 978-0-387-75613-4 (eBook) DOI 10.1007/978-0-387-75613-4 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2013953328 © Springer Science+Business Media New York 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer.
    [Show full text]
  • Adjunctive Use of Rifampin for the Treatment of Staphylococcus Aureus Infections: a Systematic Review of the Literature
    REVIEW ARTICLE Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections A Systematic Review of the Literature Joshua Perlroth, MD; Melissa Kuo, MD; Jennifer Tan, MHS; Arnold S. Bayer, MD; Loren G. Miller, MD, MPH Background: Staphylococcus aureus causes severe life- efit of adjunctive rifampin use, particularly in osteomy- threatening infections and has become increasingly com- elitis and infected foreign body infection models; however, mon, particularly methicillin-resistant strains. Rif- many studies failed to show a benefit of adjunctive therapy. ampin is often used as adjunctive therapy to treat S aureus Few human studies have addressed the role of adjunc- infections, but there have been no systematic investiga- tive rifampin therapy. Adjunctive therapy seems most tions examining the usefulness of such an approach. promising for the treatment of osteomyelitis and pros- thetic device–related infections, although studies were Methods: A systematic review of the literature to iden- typically underpowered and benefits were not always seen. tify in vitro, animal, and human investigations that com- pared single antibiotics alone and in combination with Conclusions: In vitro results of interactions between rif- rifampin therapy against S aureus. ampin and other antibiotics are method dependent and often do not correlate with in vivo findings. Adjunctive Results: The methods of in vitro studies varied substan- rifampin use seems promising in the treatment of clini- tially among investigations. The effect of rifampin therapy cal hardware infections or osteomyelitis, but more de- was often inconsistent, it did not necessarily correlate with finitive data are lacking. Given the increasing incidence in vivo investigations, and findings seemed heavily de- of S aureus infections, further adequately powered in- pendent on the method used.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Successful Treatment of Necrosed Primary Molars Using LSTR
    Avicenna J Dent Res. 2018 Dec;10(4):143-147 doi 10.34172/ajdr.2018.28 AJDR Case Report Avicenna Journal of Dental Research Successful Treatment of Necrosed Primary Molars Using LSTR Technique by a New Combination of Antibiotics: A Case Series Open Access Scan to access more free content Rezvan Rafatjou1, Sanaz Afzal Soltani2* *Correspondence to Abstract Sanaz Afzal Soltani, Introduction: In this study we used combination of amoxicillin, metronidazole and clindamycin for Email: dr.s.afzalsoltani@ treatment of 3 patients with infected primary molars until eruption of the first molars. Materials and gmail.com Tel: +989127724973 Methods: A single session LSTR was done using combination of ciprofloxacin, metronidazole and andclindamycin at the ratio of 1:1:1. Keywords: LSTR, primary Conclusions: After 12- to 13-month follow-ups, the combination can greatly help save hopeless molars, othermix infected primary molars before eruption of permanent first molars due to effective space maintenance. Received June 21, 2018 Accepted Oct. 9, 2018 ePublished Dec. 27, 2018 Citation: Rafatjou R, Afzal Soltani S. Successful treatment of necrosed primary molars using LSTR technique by a new combination of antibiotics: a case series. Avicenna J Dent Res. 2018;10(4):143-147. doi: 10.34172/ajdr.2018.28. Background Bacteria play an important role in initiation, progression Highlights and persistence of apical periodontitis (1). During ► This study reports three cases of single session LSTR (using pulp inflammation, diverse oral and foodborne combination of clindamycin, ciprofloxacin and metronidazole) for infected primary molars microorganisms invade the pulp space, form biofilm on ► The only side effect observed was early root resorption canal walls, and infiltrate the dentinal tubules (2).
    [Show full text]
  • In Vitro Activity of Rokitamycin, a New Macrolide, Against Borrelia Burgdorferi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1995, p. 1185–1186 Vol. 39, No. 5 0066-4804/95/$04.0010 Copyright q 1995, American Society for Microbiology In Vitro Activity of Rokitamycin, a New Macrolide, against Borrelia burgdorferi 1 1 2 2 M. CINCO, * D. PADOVAN, G. STINCO, AND G. TREVISAN Institute of Microbiology1 and Department of Dermatology,2 University of Trieste, 34127 Trieste, Italy Received 22 November 1994/Returned for modification 20 January 1995/Accepted 27 February 1995 The activity of rokitamycin, a new macrolide with a 16-member ring, was tested against Borrelia burgdorferi in vitro. The antibiotic had a lower MIC at which 50% of the isolates are inhibited than erythromycin, the parent 14-member macrolide, but the same MIC at which 50% of the isolates are inhibited as the other recent 14- and 15-member macrolides, like clarithromycin and azithromycin. The MBC was equal to the MIC at which 50% of the isolates are inhibited, so rokitamycin can be considered bactericidal against B. burgdorferi. The sensitivity of the Borrelia strains tested was not correlated with the particular species Burgdorferi sensu stricto, B. garinii, and B. afzelii or with the number of subcultures of the isolates. Lyme borreliosis is a very common tick-borne infection that concentration, and 100 ml was dispensed into the first well for is caused by a spirochete, Borrelia burgdorferi. The variability of each set of experiments, carefully mixed by repeated pipetting, the clinical course of the disease has made it difficult to assess and diluted twofold in each well, skipping one for growth the effectiveness of antimicrobial therapy.
    [Show full text]
  • Biotransformation of Bile Acids by Pathogenic Actinomycetes Nocardia Otitidiscaviarum and Amycolatopsis Sp
    J. Antibiot. 58(5): 356–360, 2005 THE JOURNAL OF NOTE [_ ANTIBIOTICSJ Biotransformation of Bile Acids by Pathogenic Actinomycetes Nocardia otitidiscaviarum and Amycolatopsis sp. Strains Akira Mukai, Katsukiyo Yazawa, Yuzuru Mikami, Ken-ichi Harada, Udo Gräfe Received: October 29, 2004 / Accepted: April 8, 2004 © Japan Antibiotics Research Association Abstract Three sterol-type compounds (compounds 4, 5 Detroit, USA), contain cholic acid and its derivatives: and 6) were isolated from culture broth of pathogenic cholic acid (1), taurocholic acid (2), and glycocholic acid Nocardia otitidiscaviarum IFM 0988 and Amycolatopsis (3) (Fig. 1). Furthermore, our screening studies of new sp. IFM 0703 strains which were isolated from Japanese metabolites of the cultured Nocardia and Amycolatopsis patients. The structures of the compounds were determined strains using a nutrient medium suggested the presence of by NMR and mass spectrometric analyses. The structural additional cholic acid related compounds, implying studies indicated that compound 4 is a biotransformation microbial conversion of cholic acid by pathogenic product from cholic acid derivative in a nutrient culture Nocardia. We isolated such compounds and designated medium constituent by a reductase-type enzyme, and them as compound 4 from N. otitidiscaviarum IFM 0988 the remaining two compounds 5 and 6 are also strain, and compounds 5 and 6 from Amycolatopsis sp. IFM biotransformation ones by oxidase-type enzymes. 0703 strain (Fig. 1). Subsequently, we elucidated their structures using physicochemical methods such as NMR Keywords Nocardia otitidiscaviarum, Amycolatopsis and MS. Our preliminary structural studies suggested that sp., biotransformation, cholic acid compound 4 was produced by enzymes such as reductases of N.
    [Show full text]